Every year in the U.S. alone, Chlamydia, Gonorrhea and HPV cause infertility in 50,000 women and 13,000 cases of cervical cancer. Almost all these cases are preventable with regular screenings, but issues such as lack of access, time constraints, embarrassment and pain prevent many women from taking care of themselves.
With funding from OCE and OCE’s CCR, Eve Medical is developing HerSwabTM – a device that makes it simple for women to self-collect a high-quality sample, in the privacy of their own homes, without a doctor. This reduces the barriers to screenings for women, while saving time and resources for clinics.
Jessica Ching, Eve Medical CEO, created the device as part of her final-year thesis project at OCAD University. Her patented design is attracting a lot of attention, and a lot of investment.
Ching recently received OCE’s 2011 Martin Walmsley Fellowship for $50,000. Her company also received additional funding from NSERC and won the MaRS Up-Start! Competition in 2011.
“The idea for my research was inspired by a conversation that I had with a group of women who all told me that they avoided their annual cervical cancer screening exams like the plague. When we designed this device, we really looked at it from a user’s point of view to figure out what is it that they need in order to use this device properly and to collect the best sample that they can every time.” —Jessica Ching, CEO, Eve Medical
Return on Innovation
- Expected to create 40 jobs by 2015
OCE©2011 Last updated 09/2012